Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
13.1M
-
Number of holders
-
164
-
Total 13F shares, excl. options
-
16M
-
Shares change
-
+82.4K
-
Total reported value, excl. options
-
$852M
-
Value change
-
+$1.04M
-
Put/Call ratio
-
0.78
-
Number of buys
-
79
-
Number of sells
-
-82
-
Price
-
$53.42
Significant Holders of EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) as of Q4 2017
206 filings reported holding EGRX - EAGLE PHARMACEUTICALS, INC. - Common Stock as of Q4 2017.
EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) has 164 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16M shares
.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (1.66M shares), BlackRock Inc. (1.23M shares), VICTORY CAPITAL MANAGEMENT INC (1.05M shares), Park West Asset Management LLC (1.04M shares), Hudson Executive Capital LP (971K shares), IRIDIAN ASSET MANAGEMENT LLC/CT (902K shares), STATE STREET CORP (768K shares), LSV ASSET MANAGEMENT (734K shares), First Eagle Investment Management, LLC (602K shares), and Vanguard Group Inc (570K shares).
This table shows the top 164 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.